enow.com Web Search

  1. Ads

    related to: new drugs for psoriasis

Search results

  1. Results from the WOW.Com Content Network
  2. Spesolimab - Wikipedia

    en.wikipedia.org/wiki/Spesolimab

    Spesolimab, sold under the brand name Spevigo, is a monoclonal antibody used for the treatment of generalized pustular psoriasis (GPP). [4] It is an interleukin-36 receptor (IL-36R) antagonist. [ 4 ] [ 6 ] It is given via injection into a vein.

  3. Tildrakizumab - Wikipedia

    en.wikipedia.org/wiki/Tildrakizumab

    Tildrakizumab, sold under the brand name Ilumya among others, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. [4] It is approved for the treatment of adults with moderate-to-severe plaque psoriasis in the United States and in the European Union.

  4. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.

  5. US FDA expands J&J's psoriasis drug for inflammatory bowel ...

    www.aol.com/news/us-fda-expands-j-js-223522601.html

    J&J has been betting on Tremfya, as its other blockbuster drug for psoriasis and ulcerative colitis, Stelara, is looking at a patent cliff — which occurs when a company loses its patent ...

  6. Tapinarof - Wikipedia

    en.wikipedia.org/wiki/Tapinarof

    Tapinarof, also known as benvitimod and sold under the brand name Vtama, is a medication used for the treatment of plaque psoriasis. [1] The medication is applied to the skin. [1] Besides its use in medicine, tapinarof is a naturally occurring compound found in bacterial symbionts of nematodes which has antibiotic properties. [2] [3]

  7. Deucravacitinib - Wikipedia

    en.wikipedia.org/wiki/Deucravacitinib

    Deucravacitinib, sold under the brand name Sotyktu, is a medication used for the treatment of moderate-to-severe plaque psoriasis. [7] It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth. [7] It was developed by Bristol Myers Squibb. [10]

  1. Ads

    related to: new drugs for psoriasis